Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,143,744
  • Shares Outstanding, K 536,435
  • Annual Sales, $ 28,190 M
  • Annual Income, $ 6,717 M
  • 60-Month Beta 0.60
  • Price/Sales 5.77
  • Price/Cash Flow 11.33
  • Price/Book 31.90
Trade AMGN with:

Options Overview Details

View History
  • Implied Volatility 19.92% ( -0.35%)
  • Historical Volatility 18.21%
  • IV Percentile 32%
  • IV Rank 20.50%
  • IV High 33.07% on 04/16/24
  • IV Low 16.53% on 09/01/23
  • Put/Call Vol Ratio 0.76
  • Today's Volume 11,683
  • Volume Avg (30-Day) 8,438
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 197,453
  • Open Int (30-Day) 197,334

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 4.86
  • Number of Estimates 12
  • High Estimate 5.12
  • Low Estimate 4.46
  • Prior Year 5.00
  • Growth Rate Est. (year over year) -2.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
295.30 +3.62%
on 06/13/24
316.67 -3.37%
on 05/21/24
-6.48 (-2.07%)
since 05/17/24
3-Month
260.68 +17.38%
on 04/19/24
322.60 -5.15%
on 05/03/24
+35.09 (+12.95%)
since 03/18/24
52-Week
218.44 +40.08%
on 07/07/23
329.72 -7.20%
on 02/05/24
+76.33 (+33.24%)
since 06/16/23

Most Recent Stories

More News
Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

GILD : 63.15 (-1.74%)
$NASX : 17,862.23 (+0.03%)
AMGN : 305.99 (+0.89%)
How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

REGN : 1,039.11 (-0.60%)
IBB : 134.38 (-0.78%)
AMGN : 305.99 (+0.89%)
Is Amgen Stock Outperforming the S&P 500?

Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.

AMGN : 305.99 (+0.89%)
$SPX : 5,487.03 (+0.25%)
LLY : 891.46 (+0.73%)
NVO : 140.80 (+0.31%)
BIIB : 223.65 (-1.24%)
Is Geron Stock a Buy Following Its First New Drug Approval?

Find out if the high-flying biotech stock can keep on climbing higher.

AMGN : 305.99 (+0.89%)
GERN : 4.49 (-3.85%)
Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains...

ABBV : 171.36 (+0.99%)
AMGN : 305.99 (+0.89%)
$SPX : 5,487.03 (+0.25%)
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

There's probably a big enough pie here for everyone to get a slice.

LLY : 891.46 (+0.73%)
AMGN : 305.99 (+0.89%)
AZN : 78.42 (-1.12%)
VKTX : 50.64 (-2.65%)
3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference...

ARKK : 43.68 (-1.02%)
NTLA : 24.80 (-1.47%)
PRME : 6.28 (-1.10%)
BEAM : 23.17 (-3.58%)
XBI : 89.70 (-0.98%)
WFC : 59.05 (+1.39%)
VKTX : 50.64 (-2.65%)
CRSP : 60.57 (-1.97%)
ABBV : 171.36 (+0.99%)
AMGN : 305.99 (+0.89%)
BMY : 40.81 (-0.39%)
GILD : 63.15 (-1.74%)
Where Will Amgen Be in 3 Years?

The Amgen of 2027 could be much be larger than some investors expect.

AMGN : 305.99 (+0.89%)
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?

The gold rush for obesity medications just got a bit more intense.

AMGN : 305.99 (+0.89%)
LLY : 891.46 (+0.73%)
NVO : 140.80 (+0.31%)
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
MRK : 127.99 (+0.38%)
RHHBY : 34.9800 (+1.16%)
AMGN : 305.99 (+0.89%)
BNTX : 86.27 (-2.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 312.22
2nd Resistance Point 309.38
1st Resistance Point 307.69
Last Price 305.99
1st Support Level 303.16
2nd Support Level 300.32
3rd Support Level 298.63

See More

52-Week High 329.72
Last Price 305.99
Fibonacci 61.8% 287.21
Fibonacci 50% 274.08
Fibonacci 38.2% 260.95
52-Week Low 218.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar